Recursion Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Recursion Pharmaceuticals's estimated annual revenue is currently $328M per year.
- Recursion Pharmaceuticals received $20.5M in venture funding in June 2018.
- Recursion Pharmaceuticals's estimated revenue per employee is $321,600
- Recursion Pharmaceuticals's total funding is $465.4M.
Employee Data
- Recursion Pharmaceuticals has 1020 Employees.
- Recursion Pharmaceuticals grew their employee count by -13% last year.
Recursion Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CBO/CEO/Chief Corporate Development Officer. | Reveal Email/Phone |
2 | Co-Founder & CEO | Reveal Email/Phone |
3 | Co-Founder and CEO | Reveal Email/Phone |
4 | VP, Business Operations & Chief Staff | Reveal Email/Phone |
5 | Senior Executive Assistant to Chief Business Officer and Chief People Officer | Reveal Email/Phone |
6 | Director Research Operations and Chief Staff to COO | Reveal Email/Phone |
7 | VP, Digital Chemistry | Reveal Email/Phone |
8 | VP, High Throughput Operations | Reveal Email/Phone |
9 | Controller | Reveal Email/Phone |
10 | VP High Throughput Screening | Reveal Email/Phone |
Recursion Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $8.2M | 41 | -11% | N/A | N/A |
#2 | $18.3M | 91 | 6% | N/A | N/A |
#3 | $20.5M | 102 | 0% | N/A | N/A |
#4 | $8.4M | 42 | 11% | N/A | N/A |
#5 | $18.1M | 90 | 38% | N/A | N/A |
#6 | $12.9M | 64 | 21% | N/A | N/A |
#7 | $5.6M | 28 | -10% | N/A | N/A |
#8 | $51.9M | 258 | 25% | N/A | N/A |
#9 | $7.2M | 36 | 6% | N/A | N/A |
#10 | $7.2M | 36 | 33% | N/A | N/A |
What Is Recursion Pharmaceuticals?
Recursion Pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. Our platform has resulted in the massive parallelization of drug discovery. We have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. We partner or out-license these leads to major pharmaceutical companies early in development. Our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$465.4M
Total Funding
1020
Number of Employees
$328M
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Recursion Pharmaceuticals News
Get Recursion Pharmaceuticals alerts: On Thursday, April 7th, Christopher Gibson sold 36,718 shares of Recursion Pharmaceuticals stock. The...
Recursion Pharmaceuticals (NASDAQ:RXRX Get Rating) was downgraded by equities research analysts at Bank of America from a buy rating to...
SALT LAKE CITY (AP) _ Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $64.9 million in its fourth quarter.
Recursion, a Salt Lake City, UT-based digital biology company industrializing drug discovery, raised $239m in Series D financing. The round was led by Leaps by Bayer, the impact investment arm of Bayer AG, with participation from new investors Casdin Capital, Catalio Capital Management, LP, Lau ...
Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, kidney and more. Sponsored by Agilent Technologies How would you like to win free bench space ...
Other Companies in Salt Lake City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $190.2M | 1023 | -1% | $34.1M |
#2 | $505.7M | 1032 | -4% | N/A |
#3 | $303.7M | 1033 | N/A | N/A |
#4 | $515.5M | 1043 | 2% | N/A |
#5 | $15M | 1044 | 5% | N/A |
Recursion Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-12-08 | $2.6M | Undisclosed | Article | |
| 2016-10-04 | $12.9M | A | Lux Capital | Article |
| 2016-11-23 | $2.2M | A | Felicis Ventures | Article |
| 2017-02-10 | $4.0M | Undisclosed | Square 1 Bank | Article |
| 2017-10-04 | $60.0M | B | Data Collective (DCVC) | Article |
| 2018-06-06 | $20.5M | Undisclosed | Square 1 Bank | Article |